62774-90-7

Usage

Uses

Used in Pharmaceutical Industry:
2,6-Dichloro-4-methyl-3-pyridinecarboxylic acid is used as an antibiotic for treating a variety of bacterial infections due to its broad-spectrum activity against both gram-negative and gram-positive bacteria. It is particularly effective for urinary tract infections, respiratory tract infections, skin infections, and other bacterial illnesses, making it a commonly prescribed medication in clinical settings.
Used in Antimicrobial Therapy:
In the field of antimicrobial therapy, 2,6-Dichloro-4-methyl-3-pyridinecarboxylic acid serves as a critical component in the treatment of infections caused by antibiotic-resistant bacteria. Its ability to target essential bacterial enzymes makes it a valuable tool in combating drug-resistant strains and managing complex infections.
Used in Research and Development:
2,6-Dichloro-4-methyl-3-pyridinecarboxylic acid is also utilized in research and development for the study of bacterial resistance mechanisms, the development of new antibiotics, and the understanding of the mode of action of fluoroquinolones. This contributes to the advancement of knowledge in microbiology and the discovery of novel therapeutic agents.
Used in Veterinary Medicine:
In veterinary medicine, 2,6-Dichloro-4-methyl-3-pyridinecarboxylic acid is employed as an antibiotic to treat bacterial infections in animals. It helps in managing infections in livestock, poultry, and pets, ensuring the health and well-being of animals and contributing to the prevention of zoonotic diseases.
Used in Public Health:
2,6-Dichloro-4-methyl-3-pyridinecarboxylic acid plays a significant role in public health by being a key component in the treatment of bacterial infections in community settings. Its broad-spectrum activity and effectiveness against various bacterial pathogens make it an essential antibiotic in the management of infectious diseases at the population level.

InChI:InChI=1/C7H5Cl2NO2/c1-3-2-4(8)10-6(9)5(3)7(11)12/h2H,1H3,(H,11,12)

Upstream product

• 38841-54-2 2,6-dichloro-4-methyl-3-pyridinecarboxamide 
• 875-35-4 2,6-dichloro-4-methylnicotinonitrile 
• 5444-02-0 3-cyano-4-methyl-6-hydroxypyrid-2-one 
• 91591-70-7 2,6-dichloro-4-methyl-3-pyridinecarboxaldehyde 

Downstream Products

• 220559-34-2 methyl 4.6-dichloro-3-(diethylamino)furo[3,4-c]pyridine-1-carboxylate 
• 91591-70-7 2,6-dichloro-4-methyl-3-pyridinecarboxaldehyde 
• 1373485-85-8 2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(4-fluorophenyl)-methylamino]-4-methyl-pyridine-3-carboxylic acid amide 
• 1373488-85-7 2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(3-oxo-morpholin-4-yl)-pyridine-3-carboxylic acid amide 
• 1373488-37-9 2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-[(3S)-3-(hydroxymethyl)-morpholin-4-yl]-4-methyl-pyridine-3-carboxylic acid amide 
• 1373486-98-6 2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-(methyl-pyridin-3-yl-amino)-pyridine-3-carboxylic acid amide 
• 1373485-98-3 2-ethyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide 
• 1373485-84-7 2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-6-(3-hydroxy-azetidin-1-yl)-4-methyl-pyridine-3-carboxylic acid amide 
• 1373488-72-2 6-(1,1-dioxo-[1,4]thiazinan-4-yl)-2-ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide 
• 1373489-59-8 2-chloro-6-(1,1-dioxo-[1,4]thiazinan-4-yl)-2-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide 
• 1373489-58-7 2-chloro-N-(3-fluorobenzyl)-4-methyl-6-thiomorpholino-pyridine-3-carboxylic acid amide 
• 1373485-99-4 N-[(3-fluorophenyl)-methyl]-2-isopropyl-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide 
• 1373485-97-2 N-[(3-fluorophenyl)-methyl]-2-(2-methoxy-ethoxy)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide 
• 1373489-50-9 6-chloro-2-ethylamino-N-[(3-fluorophenyl)-methyl]-4-methyl-pyridine-3-carboxylic acid amide 

Relevant academic research and scientific papers

Structure-based amelioration of PXR transactivation in a novel series of macrocyclic allosteric inhibitors of HIV-1 integrase

Previous studies have identified a series of imidazo[1,2-a]pyridine (IZP) derivatives as potent allosteric inhibitors of HIV-1 integrase (ALLINIs) and virus infection in cell culture. However, IZPs were also found to be relatively potent activators of the pregnane-X receptor (PXR), raising the specter of induction of CYP-mediated drug disposition pathways. In an attempt to modify PXR activity without affecting anti-HIV-1 activity, rational structure-based design and modeling approaches were used. An X-ray cocrystal structure of (S,S)-1 in the PXR ligand binding domain (LBD) allowed an examination of the potential of rational structural modifications designed to abrogate PXR. The introduction of bulky basic amines at the C-8 position provided macrocyclic IZP derivatives that displayed potent HIV-1 inhibitory activity in cell culture with no detectable PXR transactivation at the highest concentration tested.

IMIDAZO[1,2-A]PYRIDINE DERIVATIVES FOR USE AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.

1,6-naphthyridine derivatives and their use to treat diabetes and related disorders

The invention relates generally to naphthyridine derivatives of the formula wherein one of U, X, Y and Z is nitrogen and the others are C—R, where R is hydrogen or a substituent. More specifically, the invention relates to 1,6-naphthyridine derivatives and pharmaceutical compositions containing such derivatives. Methods of the invention comprise administration of a naphthyridine derivative of the invention for the treatment of diabetes and related disorders.

Synthesis of some halogen- and nitro-substituted nicotinic acids and their fragmentation under electron impact

Features of electrophilic and nucleophilic substitution under chlorination and nitration reactions conditions have been investigated for 6-hydroxy- and 6-methyl-substituted derivatives of 3-cyano-4-methyl-2(1H)-pyridones. The polychloro- and nitro-substituted 3-cyano-4-methylpyridines obtained were used as synthons in the synthesis of some polyhalo- and nitro-substituted nicotinic acids and their amides. The fragmentation pathways of the synthesized compounds under electron impact have been studied.

Antibacterial compounds

Antibacterials having formula (I) and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates used in the processes, compositions containing the compounds, and methods of prophylaxis and treatment of bacterial infections using the compounds are disclosed.

Synthesis and Reactions of a Stable o-Quinoid 10-π-Electron System, Furo[3,4-c]pyridine

Methyl 4,6-dichloro-3-(diethylamino)furo[3,4-c]pyridine-1-carboxylate (6), an intermediate in the Hamaguchi-Ibata reaction involving the RhII-catalyzed intramolecular reaction of a diazo group with the carbonyl of an adjacent amido group, has been isolated and characterized. PM3 calculations reveal the heat of formation (ΔHf) of this remarkably stable molecule to be -77.7 kcal/mol. Compound 6 undergoes a facile Diels-Alder cycloaddition with a variety of dienophiles to give polysubstituted isoquinoline derivatives via ring opening of initially formed cycloadducts. In each case the cycloaddition proceeds with high regioselectivity, with the electron-withdrawing group located ortho to the amino group. The most favorable FMO interaction is between the HOMO of the azaisobenzofuran 6 and the LUMO of the dienophile. The atomic coefficient at the ester carbon of the azaisobenzofuran 6 is larger than the amino center, and this nicely accommodates the observed regioselectivity.

Photochromism and photoreactivity of 2,6-dichloro-4-methyl-3-pyridinecarboxaldehyde in the solid state

Photochromism of the title compound and its photoreactivity on prolonged UV irradiation leading to products including the benzocyclobutenol 2, presumably formed by electrocyclization of an (E)-o-xylylenol intermediate in the solid state, is described. (C)